Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of AK101 in Plaque Psoriasis
NCT05509361Phase 3Completed
- Sponsor
- Akeso, Inc.
- Start
- Apr 2022
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ebdarokimab in plaque psoriasis, sponsored by Akeso, Inc. Primary endpoint: Occurrence of Treatment-Emergent Adverse Event at 52 weeks. Started Apr 2022; status: completed.
02
Drugs
ebdarokimab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05509361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05509361.